UNLIMITED TURBO LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 17:30:01 26/06/2024 BST | ||
| 4.715 EUR | -4.84% |
|
| Current month | +27.78% | ||
| 1 month | +22.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 4.715 | -4.84% |
| 25/06/24 | 4.955 | +10.73% |
| 24/06/24 | 4.475 | -1.10% |
| 21/06/24 | 4.525 | -1.95% |
| 20/06/24 | 4.615 | +4.77% |
Real-time Euronext Paris
Last update June 26, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| PS4NB | |
| ISIN | NLBNPNL2O250 |
| Date issued | 26/02/2024 |
| Strike | 676.6 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.045 € |
|---|---|
| Lowest since issue | 2.27 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
938.1
DKK
Spread / Average Target
-6.84%
- Stock Market
- Certificates
- PS4NB Certificat
